In a nutshell This study is investigating the best dose and effectiveness of brentuximab vedotin (Adcetris) combined with ICE (ifosfamide, carboplatin, etoposide) for Hodgkin’s lymphoma (HL) patients with relapsed or refractory (not responding to treatment) disease. The main outcomes to be measured include the tolerated dose without unacceptable...
Read MoreHodgkin’s lymphoma Posts on Medivizor
Evaluating the long-term risk of cardiovascular mortality in lymphoma survivors
In a nutshell This study investigated the long-term risk of cardiovascular mortality (death due to heart and blood vessel disease) among lymphoma survivors, compared to the general population. This study concluded that lymphoma survivors have a higher cardiovascular mortality risk compared to the general population. Some background Advances in...
Read MoreClinical Trials Today
Prior to the 20th century, most people lived about 47 years in the developed world because of infectious diseases. In 1940, the first use of penicillin to treat infectious diseases occurred and penicillin became available in 1945 to the general public. Science and research conducted throughout the 1950s, 60s, and 70s, created more antibiotics so that life...
Read MoreAn update on the treatment of unresponsive Hodgkin lymphoma.
In a nutshell This paper reviewed the treatment of Hodgkin lymphoma unresponsive to certain treatments. The treatment guidelines for this type of Hodgkin lymphoma were then updated. Some background Hodgkin lymphoma (HL) is an uncommon type of cancer of the lymph nodes. Many patients are cured by treatment with chemotherapy and stem cell...
Read MoreA 2018 update on Hodgkin lymphoma
In a nutshell This review paper analysed the current status of Hodgkin lymphoma research. Following this analysis, guidelines for the diagnosis and treatment of Hodgkin lymphoma were made. Some background Hodgkin lymphoma (HL) is a rare form of cancer which affects B cells (a type of white blood cell). It is necessary to determine which stage of the...
Read MoreInvestigating bone loss in adult patients with lymphoma or leukemia
In a nutshell This study investigated the occurrence and impact of bone loss in adult patients with lymphoma and leukemia. This study concluded that these patients have significant bone loss compared to the general population. Some background Bone loss is a known consequence of many cancers and their treatments. In healthy adults, bone loss is...
Read MoreAn investigation into the effects of Hodgkin lymphoma on cognition
In a nutshell This study investigated the effects of chemotherapy on cancer-related cognitive impairment in patients with Hodgkin lymphoma. The main finding was that patients with Hodgkin lymphoma who have been treated with chemotherapy experienced more cognitive decline than individuals without. Some background Chemotherapy is commonly used to treat...
Read MoreCancer Vaccines
When I think of vaccines, I think of the MMRV (measles, mumps, rubella and varicella) vaccines which help our bodies establish immunity against diseases that used to kill. Now, there are vaccines being created for cancer. The rise of cancer vaccines According to Dr. Nora Disis, an oncologist and researcher in cancer vaccines at the University of...
Read MoreUmbilical cord blood transplantation for Hodgkin’s lymphoma
In a nutshell This study investigated the outcomes of umbilical cord blood transplantation in pretreated patients with Hodgkin’s lymphoma. The authors concluded that this procedure is a feasible treatment option for these patients. Some background Patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma have...
Read MoreReviewing treatment options for very high-risk HL
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read MoreReviewing treatment options for very high-risk HL
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read MorePre-stem cell transplant BEAM versus FEAM for Hodgkin’s lymphoma
In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read More
